Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

6 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.

Zinc, multivitamins do not attenuate systemic inflammation, EED in babies

01 Jul 2019
Oral nutritional supplements: top 3 guidelines for pharmacists

Zinc or multivitamin supplements do not appear to suppress systemic inflammation nor reduce markers of environmental enteric dysfunction (EED) in infants, a recent Tanzania study has found.

A total of 590 infants were randomly assigned to receive zinc only (n=156; mean age, 5.9±0.32 weeks; 46.8 percent male), multivitamins only (n=142; mean age, 5.9±0.32 weeks; 47.2 percent male), both zinc and multivitamins (n=143; mean age, 5.9±0.36 weeks; 49.0 percent male), or placebo (n=149; mean age, 5.9±0.29 weeks; 55.7 percent male). Enzyme-linked immunosorbent assay was used to measure markers of EED, systemic inflammation and growth.

At any time point, researchers observed largely no significant differences in EED, growth and systemic inflammation marker levels between infants who were vs were not given zinc supplements. For instance, 6-month values of alpha-1-acid glycoprotein (AGP; 72.58±34.88 vs 74.51±36.01 g/L; p=0.47) and C-reactive protein (CRP; 3.43±8.17 vs 3.48±7.88 mg/L; p=0.95) were similar between groups.

The only exception was insulin-like growth factor binding protein-3, which was significantly higher in those who were not given zinc (1,019.10±333.01 vs 981.13±297.59 ng/mL; p=0.03).

A similar trend was observed for multivitamin supplementation. At any time point, infants who were vs were not given multivitamins showed comparable levels of markers, such as 6-month AGP (74.35±36.84 vs 72.81±34.12 g/L; p=0.54) and CRP (3.58±8.78 vs 3.33±7.23 mg/L; p=0.73). In contrast, antilipopolysaccharide immunoglobulin G levels at 6 months were significantly higher in those who were given multivitamin supplementation (1.41±0.61 vs 1.26±0.65; p=0.006).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

6 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.
Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.